Enrique Grande, One Oncology Madrid Program Director of Quirónsalud, Adjunct Professor at The University of Texas MD Anderson Cancer Center, shared on LinkedIn:
“On European Urology Oncology – Tumor-informed ctDNA monitoring as a real-time prognostic biomarker in la/mUC treated with EV±pembrolizumab (n=110, 545 plasma samples).
On-treatment ctDNA positivity consistently associated with inferior PFS and OS across all time intervals. Early ctDNA clearance enriched among radiographic responders.”
Title: Prognostic Implications of Personalized Circulating Tumor DNA Testing in Patients with Advanced Urothelial Carcinoma Treated with Enfortumab Vedotin ± Pembrolizumab
Authors: Kevin R. Reyesa, Ryan Zhub, Cameron Herbertsc, Punashi Duttac, Ashley Wrayc, Beaux Mitchella, Syed Saqib Balkhib, Xiaolin Zhua, Carissa E. Chua, Sima P. Portena, Terence W. Friedlandera, Jonathan Choua, Steven N. Seyedina, Shruti Sharmac, Meenakshi Malhotrac, Adam C. ElNaggarc, Minetta C. Liuc, Adanma Ayanambakkamb, Vadim S. Koshkin
Other articles featuring Enrique Grande and Bladder Cancer on OncoDaily.
